Commerce Bank increased its stake in shares of Baxter International Inc (NYSE:BAX) by 1.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 61,140 shares of the medical instruments supplier’s stock after purchasing an additional 889 shares during the period. Commerce Bank’s holdings in Baxter International were worth $4,964,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the stock. Riggs Asset Managment Co. Inc. purchased a new position in Baxter International in the 4th quarter valued at approximately $25,000. FSA Wealth Management LLC purchased a new position in Baxter International in the 4th quarter valued at approximately $25,000. Mine & Arao Wealth Creation & Management LLC. purchased a new position in Baxter International in the 4th quarter valued at approximately $26,000. McIlrath & Eck LLC purchased a new position in Baxter International in the 4th quarter valued at approximately $27,000. Finally, Harwood Advisory Group LLC purchased a new position in Baxter International in the 1st quarter valued at approximately $32,000. 83.95% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have commented on BAX. SVB Leerink raised their price target on shares of Baxter International from $96.00 to $105.00 and gave the company an “outperform” rating in a research report on Friday, May 1st. TheStreet upgraded shares of Baxter International from a “c+” rating to a “b+” rating in a report on Thursday, April 30th. KeyCorp raised their price objective on shares of Baxter International from $92.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Raymond James raised their price objective on shares of Baxter International from $90.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, April 13th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Baxter International from $94.00 to $96.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Baxter International has an average rating of “Buy” and an average target price of $95.90.
Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.09. Baxter International had a net margin of 8.85% and a return on equity of 22.70%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.74 billion. During the same period last year, the firm posted $0.76 EPS. Baxter International’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities analysts expect that Baxter International Inc will post 3.29 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Friday, June 5th will be given a dividend of $0.245 per share. This is an increase from Baxter International’s previous quarterly dividend of $0.22. This represents a $0.98 annualized dividend and a yield of 1.13%. The ex-dividend date of this dividend is Thursday, June 4th. Baxter International’s dividend payout ratio (DPR) is presently 26.59%.
In other news, SVP Sean Martin bought 9,780 shares of the stock in a transaction dated Monday, March 30th. The shares were acquired at an average price of $82.19 per share, with a total value of $803,818.20. Following the completion of the acquisition, the senior vice president now directly owns 39,504 shares in the company, valued at $3,246,833.76. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Albert P. L. Stroucken sold 4,320 shares of Baxter International stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $79.64, for a total transaction of $344,044.80. Following the completion of the sale, the director now directly owns 34,018 shares in the company, valued at approximately $2,709,193.52. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Story: Does a trade war provide a risk to the global economy?
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.